Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. - Wikidata - wikimedia - TriplyDB

Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244.

Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244.

http://www.wikidata.org/entity/Q34611642

about

Hodgkin lymphoma, version 2.2015.Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of nivolumab.Clinical features and treatment outcomes of Hodgkin's lymphoma in Hong Kong Chinese.Advanced hodgkin lymphoma: a new era of therapy.Hodgkin's lymphoma therapy: past, present, and future.Incidence patterns and outcomes for hodgkin lymphoma patients in the United States Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)Hodgkin lymphoma: 2014 update on diagnosis, risk-stratification, and management.The Management of Classical Hodgkin's Lymphoma: Past, Present, and Future Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma.Current concepts and controversies in the management of early stage Hodgkin lymphoma.SEOM clinical guidelines for the treatment of Hodgkin's lymphoma.Treatment results in advanced stage Hodgkin's lymphoma: a retrospective study.Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma.Decreased Prognostic Value of International Prognostic Score in Chinese Advanced Hodgkin Lymphoma Patients Treated in the Contemporary Era.Review of the cardiac long-term effects of therapy for Hodgkin lymphoma.Management of children with high-risk Hodgkin lymphoma.State of the art in the treatment of Hodgkin lymphoma.Hodgkin lymphoma: 2012 update on diagnosis, risk-stratification, and management.The GHSG Approach to Treating Hodgkin's Lymphoma.XVII. Treatment of advanced-stage Hodgkin lymphoma.Risk-adapted strategies for the treatment of Hodgkin lymphoma.Chimeric antigen receptor T-cell therapies for lymphoma.Does Radiation Have a Role in Advanced Stage Hodgkin's or Non-Hodgkin Lymphoma?Treatment outcomes for Hodgkin lymphoma: First report from the Brazilian Prospective Registry.Hodgkin lymphoma: 2016 update on diagnosis, risk-stratification, and management.Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era.Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: A systematic review and meta-analysis of randomized clinical trials.Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis.Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation.ABVD chemotherapy with reduced radiation therapy rates in children, adolescents and young adults with all stages of Hodgkin lymphoma.Treatment of Hodgkin lymphoma with adriamycin, bleomycin, vinblastine and dacarbazine without routine granulocyte-colony stimulating factor support does not increase the risk of febrile neutropenia: a prospective cohort study.Impact of time from diagnosis to initiation of curative-intent chemotherapy on clinical outcomes in patients with classical Hodgkin lymphoma.PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome New agents in relapsed/refractory Hodgkin's lymphoma.Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective stud Granulocyte colony-stimulating factor as secondary prophylaxis of febrile neutropenia in the management of advanced-stage Hodgkin lymphoma treated with adriamycin, bleomycin, vinblastine and dacarbazine chemotherapy: a decision analysis.High frequency of primary refractory disease and low progression-free survival rate of Hodgkin's lymphoma: a decade of experience in a Latin American center.

P2860

Q30769157-93EA81D0-313F-46DD-8C62-3E87C5B87DBC Q33704061-45BA716E-49D7-410F-AC37-497463296931 Q33935351-CBC15F13-26F9-4190-B585-F8F56500D013 Q34194160-31A23C58-D470-4132-8547-54B216E5F271 Q34296914-5BEB1ACA-F1A0-414C-A8C7-E2C728FF6CE4 Q34442533-1959B326-CF74-48B2-9F9D-D189FBEB3886 Q34645722-72F5BC72-6759-4C43-9CF2-DF22DADD1530 Q34662648-DED3306E-29C4-404F-9AC0-18F8EB4186FE Q35038852-CC86E978-90AC-4BDC-B40A-1D885D8459E8 Q35564776-40362DA0-C7A6-4D8C-B7BE-BE420330FFB4 Q35671369-6A0F4D48-704F-46F4-ADF7-DC672A154929 Q35986609-65A8EF88-A94F-43E1-A3D1-89CFFEFC6EEA Q36061643-8614801C-3565-4D5F-8C76-88934974B509 Q36400264-33BF7D77-03FB-49E4-A4AC-19473DA5549A Q37091269-AAD70C4D-9A27-4068-A1E1-F1046F3BA541 Q37126978-759907F0-D950-44A8-8A87-9C34C9D42A3C Q37487600-78C810C0-5267-417B-B2AB-3A82B76925D4 Q37871620-642FD47C-1C43-4591-ADF7-04C1BDCE9A96 Q37970408-78BF6707-571B-4240-84C6-576CBDB0D8F7 Q38017914-CECAD315-5E9B-4FB3-A90C-3BACADD4D6F9 Q38059817-6DDB59FC-C3AF-4123-B97F-9BAEC8955EC5 Q38506223-75ACF0E7-CD90-4DAC-936B-2A572645BF47 Q38524025-BAE5F5C7-483B-4F18-AFC8-A1F58C3859C1 Q38591137-4399D105-0701-4325-807A-CCB8269C86D6 Q38600697-87E6FE84-892D-448F-BFCB-4FAE1FF042A6 Q38688797-E441582F-DD1F-45E3-BFBD-4A322EFCC6E9 Q38712597-86585DB2-7821-4638-B488-F77C4C0F424E Q38784099-88F05795-8816-4E94-9917-4F993BCB31DF Q39995834-5849540D-59A0-48EA-986F-B06F150B296A Q40040274-482C818A-BE6E-494E-9AFB-0D78B4872B61 Q40044179-01722322-FD85-4122-A6B0-4D16618FD6F4 Q40149586-A8254018-4DFD-4AAD-9E3B-703CA2E80E77 Q40281182-DD4A2C6B-06EF-4D22-800C-343410A2D5AD Q40319011-510AFB57-89D5-4094-BB52-48AFCD8DA3B9 Q40588449-F26D4A4B-0DBE-4995-874C-B283579C3AFB Q41069147-29A7C94D-A360-4FF1-BA28-830139185C95 Q41500227-1A44C20B-F860-4856-9BED-0CC3305C35C9 Q41728053-3A5A25FD-78B5-426F-B748-F930957FCFB4 Q44462626-0741CAB9-C5C5-42C1-95FF-9C4A3EE4A0FA Q46879226-2DFE2DC9-77CF-4994-AC0F-A14F373500E7

P2860

Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244.

http://www.wikidata.org/entity/Q34611642

description

2009 nî lūn-bûn

@nan

2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Randomized comparison of the s ...... a Group Study ISRCTN 64141244.

@ast

Randomized comparison of the s ...... a Group Study ISRCTN 64141244.

@en

Randomized comparison of the s ...... a Group Study ISRCTN 64141244.

@nl

type

label

Randomized comparison of the s ...... a Group Study ISRCTN 64141244.

@ast

Randomized comparison of the s ...... a Group Study ISRCTN 64141244.

@en

Randomized comparison of the s ...... a Group Study ISRCTN 64141244.

@nl

prefLabel

Randomized comparison of the s ...... a Group Study ISRCTN 64141244.

@ast

Randomized comparison of the s ...... a Group Study ISRCTN 64141244.

@en

Randomized comparison of the s ...... a Group Study ISRCTN 64141244.

@nl

P1433

Q34611642-71C0A7A9-426F-46D3-9E59-2EC938D2B9C7

P1476

Q34611642-54EE8A56-D68E-4ADC-9FE6-B1333AE9DE00

P2093

Q34611642-00095A95-002F-4E41-AD2B-9BAF02FA9A00

Q34611642-2069430A-676D-41BB-BD83-98458CFBFC4C

Q34611642-335AC4B8-8821-4F54-A934-4CD024DACAB6

Q34611642-50BFB8BF-C0C3-4E97-8522-82A3AACDF709

Q34611642-5253FE6C-6878-48F9-A842-6A605EDBE256

Q34611642-64817610-72B4-440C-B0C3-4173CCCEC9F8

Q34611642-7D245FF0-584E-4641-B1BE-50C6126DB549

Q34611642-99C47F69-8241-483A-86FA-A4840C018DFD

Q34611642-A00771D5-5CC9-46F4-B19A-58D117759D4D

Q34611642-A32C25E4-9AC6-4AA2-8F72-265E28BB6DD0

P304

Q34611642-00DA7D1F-D6F4-44D8-B5AD-0DAD4DA69EA8

P31

Q34611642-13FB6498-DE10-41B0-BB59-7AD0D73CE786

P356

Q34611642-51F7BCA4-E6A1-4E73-9A4F-2E210CC03C24

P407

Q34611642-C2ABB0E0-B285-44B5-B111-0283F81C2791

P433

Q34611642-0198C512-8BBD-4F5E-9E7F-2775110F5315

P478

Q34611642-058268CD-D012-495B-AA9B-95D006017AF5

P50

Q34611642-99EF8602-2927-4EF0-8F75-B5C911BAE83D

P577

Q34611642-984C4F2A-A5CA-4745-98C6-BFB47D5BDA64

P698

Q34611642-F41F8D78-9664-49D0-BB6E-EBDA2EC8372E

P356

JCO.2009.23.3239

P1433

Journal of Clinical Oncology

P1476

Randomized comparison of the s ...... a Group Study ISRCTN 64141244.

@en

P2093

Alan Horwich

http://www.w3.org/2001/XMLSchema#string

Andrew Jack

http://www.w3.org/2001/XMLSchema#string

Andrew Pettitt

http://www.w3.org/2001/XMLSchema#string

Barry W Hancock

http://www.w3.org/2001/XMLSchema#string

Ben Mead

http://www.w3.org/2001/XMLSchema#string

Bilyana Popova

http://www.w3.org/2001/XMLSchema#string

David Linch

http://www.w3.org/2001/XMLSchema#string

John Sweetenham

http://www.w3.org/2001/XMLSchema#string

Lisa Lowry

http://www.w3.org/2001/XMLSchema#string

Paul Smith

http://www.w3.org/2001/XMLSchema#string

P304

5390-5396

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2009.23.3239

http://www.w3.org/2001/XMLSchema#string

P407

P433

32

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

David Cunningham

P577

2009-09-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19738111

http://www.w3.org/2001/XMLSchema#string